


AMENDMENTS TO THE CLAIMS

Kindly amend claim 23 as provided in the following Claims Listing.

Claims Listing:

Claims 1-22 (Cancelled).

23. (Currently Amended) A method for the treatment of a pathology associated with the constriction of smooth muscle cells in a subject in need thereof, said method comprising administering to said subject a compound of formula (Ia):



in which:

- R₁ and R₂ represent a hydrogen atom,
- R₅ represents a hydrogen atom, or a linear or substituted alkyl group with 1 to 10 carbon atoms, ~~in particular a butyl group~~, or an ester of formula COOR' in which R' represents a linear or substituted alkyl group with 1 to 10 carbon atoms,
- Y represents an -OH, -SH, or -NH₂ group,
- each of R₇, R₈, R₉, and R₁₀ is, independently, ~~represent a hydrogen, atom, or at least one of R₇, R₈, R₉, or R₁₀ represents a halogen atom selected from the group comprising a chlorine, bromine, or fluorine atom, and~~

- X represents an anion.

24. (Previously Presented) The method of claim 23, wherein said pathology is a vascular disorder.

25. (Previously Presented) The method of claim 24, wherein said pathology is arterial hypertension.

26. (Previously Presented) The method of claim 23, wherein said pathology is associated with bronchoconstriction.

27. (Previously Presented) The method of claim 26, wherein said pathology is asthma.


28. (Previously Presented) The method of claim 23, wherein X is chloride, bromide, or perchlorate.

29. (Previously Presented) The method of claim 23, wherein R₅ is a butyl group.


30. (Previously Presented) The method of claim 23, wherein R' is an ethyl group.

31. (Previously Presented) The method of claim 23, wherein said compound of formula (Ia) is selected from the following compounds:


compound 13 (MPB-01)




compound 11 (MPB-26)




compound 14 (MPB-02)




compound 15 (MPB-03)




compound 16




compound 17




compound 24




compound 12 (MPB-05)




compound 18 (MPB-06)




compound 19 (MPB-07)




compound 20 (MPB-08)




compound 21 (MPB-27)




compound 25 (MPB-30)




compound 26 (MPB-29)




compound 27 (MPB-32)




compound MPB-91




compound MPB 73




compound MPB 75




compound MPB 86




compound MPB 77




compound MPB 87




compound MPB 88



compound MPB 102




compound MPB 103




32. (Previously Presented) The method of claim 23, wherein said compound of formula (Ia) is MPB-07 of the following formula:

compound 19 (MPB-07)




33. (Previously Presented) The method of claim 23, wherein said compound of formula (Ia) is MPB-91 of the following formula:

compound MPB-91




34. (Previously Presented) A compound selected from:


compound MPB 73




compound MPB 75




compound MPB 86




compound MPB 77



compound MPB 87




compound MPB 88




35. (Previously Presented) A compound selected from:

compound MPB 102



compound MPB 103



36. (Previously Presented) A pharmaceutical composition comprising a compound of claim 34 in combination with a pharmaceutically acceptable carrier.

37. (Previously Presented) A pharmaceutical composition comprising a compound of claim 35 in combination with a pharmaceutically acceptable carrier.